LiverMultiScan’s cT1 was the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled trial on the effect of Mastiha on liver inflammation and fibrosis. Over six months, cT1 decreased in participants with severe obesity, with no significant change on placebo.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?